Merck KGaA Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Belen Garijo Lopez

İcra Kurulu Başkanı

€10.5m

Toplam tazminat

CEO maaş yüzdesi	14.2%
CEO görev süresi	9.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	6.1yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

Mar 26

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Mar 05

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Feb 14

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Dec 12

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Nov 09

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Aug 15

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

May 17

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Mar 29

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?

Jan 13

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease

Oct 15

A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Sep 19

CEO Tazminat Analizi

Belen Garijo Lopez'un ücretlendirmesi Merck KGaA'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	€3b
Mar 31 2024	n/a	n/a	€3b
Dec 31 2023	€11m	€2m	€3b
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€3b
Mar 31 2023	n/a	n/a	€3b
Dec 31 2022	€11m	€2m	€3b
Sep 30 2022	n/a	n/a	€3b
Jun 30 2022	n/a	n/a	€3b
Mar 31 2022	n/a	n/a	€3b
Dec 31 2021	€9m	€1m	€3b
Sep 30 2021	n/a	n/a	€3b
Jun 30 2021	n/a	n/a	€3b
Mar 31 2021	n/a	n/a	€2b
Dec 31 2020	€7m	€1m	€2b
Sep 30 2020	n/a	n/a	€2b
Jun 30 2020	n/a	n/a	€1b
Mar 31 2020	n/a	n/a	€2b
Dec 31 2019	€6m	€1m	€1b
Sep 30 2019	n/a	n/a	€1b
Jun 30 2019	n/a	n/a	€1b
Mar 31 2019	n/a	n/a	€938m
Dec 31 2018	€7m	€1m	€1b
Sep 30 2018	n/a	n/a	€2b
Jun 30 2018	n/a	n/a	€2b
Mar 31 2018	n/a	n/a	€2b
Dec 31 2017	€6m	€1m	€3b

Tazminat ve Piyasa: Belen 'nin toplam tazminatı ($USD 11.41M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.20M ).

Tazminat ve Kazançlar: Belen 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Belen Garijo Lopez (64 yo)

9.8yrs

Görev süresi

€10,527,000

Tazminat

Ms. Belen Garijo Lopez, M.D., is Chair of Executive Board and Chief Executive Officer of MERCK Kommanditgesellschaft auf Aktien since May 01, 2021. She served as Vice Chairman of the Executive Board and De...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Belen Garijo Lopez	Chair of Executive Board & CEO	9.8yrs	€10.53m	Veri yok
Helene von Roeder	CFO & Member of Executive Board	1.3yrs	€1.23m	Veri yok
Kai Beckmann	CEO of Electronics & Member of the Executive Board	13.6yrs	€8.26m	Veri yok
Peter Guenter	CEO of Healthcare Business & Member of Executive Board	3.8yrs	€5.58m	Veri yok
Matthias Heinzel	CEO of Life Science Sector & Member of Executive Board	3.6yrs	€5.22m	Veri yok
Barbara Weiland	Chief Compliance Officer	5.3yrs	Veri yok	Veri yok
Dietmar Eidens	Head of the Global HR Business Partner Organization	9.8yrs	Veri yok	Veri yok
Frank Gotthardt	Head of Corporate & Government Relations - Europe	15.4yrs	Veri yok	Veri yok
Marc Horn	Head of Life Science Controlling	no data	Veri yok	Veri yok
Michael Heckmeier	Head of the Display Materials Business Unit for Performance Materials	7.6yrs	Veri yok	Veri yok
Hans-Joachim Neumann	Head of Integrated Supply Chain	6.1yrs	Veri yok	Veri yok
Tina Sandmann	Head of Internal Auditing	5.3yrs	Veri yok	Veri yok

6.1yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: MRK 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dietmar Oeter	Independent Member of Supervisory Board	10.5yrs	€50.80k	Veri yok
Alexander Putz	Member of Supervisory Board	4.5yrs	€50.80k	Veri yok
Stefan Palzer	Supervisory Board Member	less than a year	Veri yok	Veri yok
Barbara Lambert	Independent Member of Supervisory Board	1.3yrs	€30.50k	Veri yok
Sascha Held	Vice Chair of Supervisory Board	5.6yrs	€89.30k	Veri yok
Michael Kleinemeier	Independent Chairman of Supervisory Board	5.6yrs	€50.80k	Veri yok
Anne Lange	Independent Member of Supervisory Board	5.6yrs	€50.80k	Veri yok
Christian Raabe	Independent Member of Supervisory Board	5.6yrs	€65.80k	Veri yok
Daniel Thelen	Independent Member of Supervisory Board	5.6yrs	€65.80k	Veri yok
Simon Thelen	Independent Member of Supervisory Board	5.6yrs	€50.80k	Veri yok
Birgit Biermann	Member of Supervisory Board	2.3yrs	€50.80k	Veri yok
Katja Vila	Supervisory Board Member	less than a year	Veri yok	Veri yok

5.6yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MRK 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

Merck KGaA Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Recent updates

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Some Shareholders Feeling Restless Over Merck KGaA's (ETR:MRK) P/E Ratio

Is There An Opportunity With Merck KGaA's (ETR:MRK) 44% Undervaluation?

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Here's Why Merck KGaA (ETR:MRK) Can Manage Its Debt Responsibly

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Some Confidence Is Lacking In Merck KGaA's (ETR:MRK) P/E

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 48% Above Its Share Price

First quarter 2024 earnings: EPS exceeds analyst expectations

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA (ETR:MRK) Will Pay A Dividend Of €2.20

Upcoming dividend of €2.20 per share

Merck KGaA (ETR:MRK) Is Paying Out A Dividend Of €2.20

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Merck KGaA (ETR:MRK) Has Affirmed Its Dividend Of €2.20

Dividend of €2.20 announced

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

We Think Merck KGaA (ETR:MRK) Can Stay On Top Of Its Debt

There's Reason For Concern Over Merck KGaA's (ETR:MRK) Price

Merck KGaA's (ETR:MRK) Intrinsic Value Is Potentially 77% Above Its Share Price

Investor sentiment deteriorates as stock falls 15%

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Does Merck KGaA (ETR:MRK) Have A Healthy Balance Sheet?

Is There An Opportunity With Merck KGaA's (ETR:MRK) 49% Undervaluation?

Second quarter 2023 earnings: Revenues exceed analyst expectations

Merck KGaA, Annual General Meeting, Apr 26, 2024

Is Merck KGaA (ETR:MRK) A Risky Investment?

Are Investors Undervaluing Merck KGaA (ETR:MRK) By 36%?

First quarter 2023 earnings: Revenues in line with analyst expectations

Merck Announces CFO Changes

Upcoming dividend of €2.20 per share at 1.3% yield

These 4 Measures Indicate That MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Is Using Debt Reasonably Well

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €2.20

Full year 2022 earnings: Revenues in line with analyst expectations

Estimating The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Stay On Top Of Its Debt

Third quarter 2022 earnings: Revenues exceed analyst expectations

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Trading At A 50% Discount?

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

Second quarter 2022 earnings: Revenues exceed analyst expectations

Does MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Have A Healthy Balance Sheet?

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of €1.85 per share

MERCK Kommanditgesellschaft auf Aktien's (ETR:MRK) Dividend Will Be Increased To €1.85

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Q2, 2022 Results on Aug 04, 2022

Is MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) A Risky Investment?

Third quarter 2021 earnings released

We Think MERCK Kommanditgesellschaft auf Aktien (ETR:MRK) Can Manage Its Debt With Ease

A Look At The Intrinsic Value Of MERCK Kommanditgesellschaft auf Aktien (ETR:MRK)

Price target increased to €195

Price target increased to €170

Second quarter 2021 earnings released: EPS €1.71 (vs €0.67 in 2Q 2020)

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company